CARGO is advancing what will potentially be a first and best-in-class autologous CD22 chimeric antigen receptor T-cell (CAR T) therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/01/23	$200,000,000	Series A	Ally Bridge Group Cormorant Asset Management Emerson Collective Janus Henderson Investors Nextech Invest Perceptive Xontogeny Venture Fund Piper Heartland Healthcare Capital Red Tree Venture Captial RTW Investments Samsara BioCapital T. Rowe Price Associates Third Rock Ventures Wellington Management Company	undisclosed